Cargando…

Long-Lasting Proteinaceous Nanoformulation for Tumor Imaging and Therapy

[Image: see text] Nanodrugs have attracted increasing interest in drug delivery and disease treatment. However, the cumbersome preparation process and the poor biocompatibility of nanodrugs obstruct their clinical translation. In this study, we utilized a self-assembly strategy to develop a low-toxi...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Lai, Gu, Xinquan, Jiang, Fuquan, Li, Bo, Lu, Shuang, Wang, Fan, Sun, Yao, Liu, Kai, Li, Jingjing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2022
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9453795/
https://www.ncbi.nlm.nih.gov/pubmed/36092568
http://dx.doi.org/10.1021/acsomega.2c03561
_version_ 1784785218278785024
author Zhao, Lai
Gu, Xinquan
Jiang, Fuquan
Li, Bo
Lu, Shuang
Wang, Fan
Sun, Yao
Liu, Kai
Li, Jingjing
author_facet Zhao, Lai
Gu, Xinquan
Jiang, Fuquan
Li, Bo
Lu, Shuang
Wang, Fan
Sun, Yao
Liu, Kai
Li, Jingjing
author_sort Zhao, Lai
collection PubMed
description [Image: see text] Nanodrugs have attracted increasing interest in drug delivery and disease treatment. However, the cumbersome preparation process and the poor biocompatibility of nanodrugs obstruct their clinical translation. In this study, we utilized a self-assembly strategy to develop a low-toxicity, long-lasting nanodrug for the effective treatment and real-time monitoring of bladder tumors. The accurate self-assembly of compatible raw materials allowed for an encapsulation rate of 43.7% for insoluble erdafitinib. Interestingly, robust therapeutic effects and reduced side effects could be realized simultaneously using this nanodrug, enabling broader scenarios for the clinical application of erdafitinib. Furthermore, the nanodrug exhibited a significantly prolonged in vivo half-life (14.4 h) and increased bioavailability (8.0 μg/mL·h), which were 8.3 times and 5.0 times higher than those of its nonformulated counterpart. Also, it is worth mentioning that the introduction of a fluorescent protein module into the nanodrug brought up a novel possibility for real-time feedback on the therapeutic response. In conclusion, this research revealed a versatile technique for developing low-toxicity, long-acting, and multifunctional nanoformulations, paving the way for multidimensional therapy of malignant tumors.
format Online
Article
Text
id pubmed-9453795
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-94537952022-09-09 Long-Lasting Proteinaceous Nanoformulation for Tumor Imaging and Therapy Zhao, Lai Gu, Xinquan Jiang, Fuquan Li, Bo Lu, Shuang Wang, Fan Sun, Yao Liu, Kai Li, Jingjing ACS Omega [Image: see text] Nanodrugs have attracted increasing interest in drug delivery and disease treatment. However, the cumbersome preparation process and the poor biocompatibility of nanodrugs obstruct their clinical translation. In this study, we utilized a self-assembly strategy to develop a low-toxicity, long-lasting nanodrug for the effective treatment and real-time monitoring of bladder tumors. The accurate self-assembly of compatible raw materials allowed for an encapsulation rate of 43.7% for insoluble erdafitinib. Interestingly, robust therapeutic effects and reduced side effects could be realized simultaneously using this nanodrug, enabling broader scenarios for the clinical application of erdafitinib. Furthermore, the nanodrug exhibited a significantly prolonged in vivo half-life (14.4 h) and increased bioavailability (8.0 μg/mL·h), which were 8.3 times and 5.0 times higher than those of its nonformulated counterpart. Also, it is worth mentioning that the introduction of a fluorescent protein module into the nanodrug brought up a novel possibility for real-time feedback on the therapeutic response. In conclusion, this research revealed a versatile technique for developing low-toxicity, long-acting, and multifunctional nanoformulations, paving the way for multidimensional therapy of malignant tumors. American Chemical Society 2022-08-24 /pmc/articles/PMC9453795/ /pubmed/36092568 http://dx.doi.org/10.1021/acsomega.2c03561 Text en © 2022 The Authors. Published by American Chemical Society https://creativecommons.org/licenses/by-nc-nd/4.0/Permits non-commercial access and re-use, provided that author attribution and integrity are maintained; but does not permit creation of adaptations or other derivative works (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Zhao, Lai
Gu, Xinquan
Jiang, Fuquan
Li, Bo
Lu, Shuang
Wang, Fan
Sun, Yao
Liu, Kai
Li, Jingjing
Long-Lasting Proteinaceous Nanoformulation for Tumor Imaging and Therapy
title Long-Lasting Proteinaceous Nanoformulation for Tumor Imaging and Therapy
title_full Long-Lasting Proteinaceous Nanoformulation for Tumor Imaging and Therapy
title_fullStr Long-Lasting Proteinaceous Nanoformulation for Tumor Imaging and Therapy
title_full_unstemmed Long-Lasting Proteinaceous Nanoformulation for Tumor Imaging and Therapy
title_short Long-Lasting Proteinaceous Nanoformulation for Tumor Imaging and Therapy
title_sort long-lasting proteinaceous nanoformulation for tumor imaging and therapy
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9453795/
https://www.ncbi.nlm.nih.gov/pubmed/36092568
http://dx.doi.org/10.1021/acsomega.2c03561
work_keys_str_mv AT zhaolai longlastingproteinaceousnanoformulationfortumorimagingandtherapy
AT guxinquan longlastingproteinaceousnanoformulationfortumorimagingandtherapy
AT jiangfuquan longlastingproteinaceousnanoformulationfortumorimagingandtherapy
AT libo longlastingproteinaceousnanoformulationfortumorimagingandtherapy
AT lushuang longlastingproteinaceousnanoformulationfortumorimagingandtherapy
AT wangfan longlastingproteinaceousnanoformulationfortumorimagingandtherapy
AT sunyao longlastingproteinaceousnanoformulationfortumorimagingandtherapy
AT liukai longlastingproteinaceousnanoformulationfortumorimagingandtherapy
AT lijingjing longlastingproteinaceousnanoformulationfortumorimagingandtherapy